• Policy
• Approval of Moderna's COVID-19 vaccine is imminent
• by Lee, Tak-Sun Apr 9, 2021 05:55am

• Company
• Tagrisso’s 1st-line reimbursement rejected once again
• by Eo, Yun-Ho Apr 9, 2021 05:55am

• Company
• Qsimia's sales exceeded ₩200 billion
• by An, Kyung-Jin Apr 9, 2021 05:55am

• Company
• Betadine, disposes of 3 months of advertising suspension
• by Nho, Byung Chul Apr 8, 2021 05:55am

• Policy
• Review underway for nation's first DPP-4+SGLT-2 inhibitor
• by Lee, Tak-Sun Apr 8, 2021 05:55am

• Policy
• Novo applies for approval of the first oral GLP-1 treatment
• by Lee, Tak-Sun Apr 8, 2021 05:55am

• Company
• Zytiga listed as a prostate cancer selective benefit
• by Apr 8, 2021 05:55am

• Company
• One-on-one briefing sessions with doctors are not allowed
• by Apr 8, 2021 05:55am

• Policy
• The NHIS sequentially began managing the entire drug cycle
• by Lee, Hye-Kyung Apr 8, 2021 05:54am

• Company
• Tumor-agnostic ‘Rozlytrek’ seeks PE exemption
• by Eo, Yun-Ho Apr 7, 2021 06:03am